Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: Involvement of BDNF and Akt/GSK-3β signaling pathway

Neurobiology of Learning and Memory

Volumn 106, Issue , 2013, Pages 134-144

  Hoppe, Juliana B ^a   Coradini, Karine ^a   Frozza, Rudimar L ^b   Oliveira, Claudia M ^a   Meneghetti, André B ^a   Bernardi, Andressa ^c   Pires, Elisa Simões ^a   Beck, Ruy C R ^a   Salbego, Christianne G ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Akt GSK 3 pathway; Alzheimer's disease; BDNF; Curcumin; Hippocampus; Lipid core nanocapsules; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3BETA; NANOCAPSULE; PROTEIN KINASE B; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; MALE; MEMORY; MENTAL PERFORMANCE; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ZETA POTENTIAL;

AKT/GSK-3Β PATHWAY; ALZHEIMER'S DISEASE; BDNF; CURCUMIN; HIPPOCAMPUS; LIPID-CORE NANOCAPSULES; Β-AMYLOID;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; COGNITION DISORDERS; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MALE; MEMORY; NEURONS; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SYNAPTOPHYSIN;

EID: 84883278654     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2013.08.001     Document Type: Article

References (75)

1. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 2007, 4:807-818.
2. Avila J., León-Espinosa G., García E., García-Escudero V., Hernández F., Defelipe J. Tau phosphorylation by GSK3 in different conditions. International Journal of Alzheimers Disease 2012, 2012:578373.
3. Begum A.N., Jones M.R., Lim G.P., Morihara T., Kim P., Heath D.D., et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 2008, 326:196-208.
4. Benvegnú D.M., Barcelos R.C., Boufleur N., Pase C.S., Reckziegel P., Flores F.C., et al. Haloperidol-loaded polysorbate coated polymeric nanocapsules decrease its adverse motor side effects andoxidative stress markers in rats. Neurochemistry International 2012, 61:623-631.
5. Bernardi A., Frozza R.L., Meneghetti A., Hoppe J.B., Battastini A.M., Pohlmann A.R., et al. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. International Journal of Nanomedicine 2012, 7:4927-4942.
6. Bevins R.A., Besheer J. Object recognition in rats and mice: A one-trial non-matching-to-sample learning task to study 'recognition memory'. Nature Protocols 2006, 1:1306-1311.
7. Broadbent N.J., Gaskin S., Squire L.R., Clark R.E. Object recognition memory and the rodent hippocampus. Learn Memory 2010, 17:5-11.
8. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and independent control of neuronal survival by the PI3K/Akt signaling pathway. Current Opinion in Neurobiology 2001, 11:297-305.
9. Bulcão R.P., Freitas F.A., Venturini C.G., Dallegrave E., Durgante J., Göethel G., et al. Acute and subchronic toxicity evaluation of poly(epsilon-caprolactone) lipid-core nanocapsules in rats. Toxicological Sciences 2013, 132:162-176.
10. Canas P.M., Porciúncula L.O., Cunha G.M.A., Silva C.G., Machado N.J., et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β-amyloid peptides via p38 mitogenactivated protein kinase pathway. Journal of Neuroscience 2009, 29:14741-14751.
11. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: A play in three Akt. Genes & Development 1999, 13:2905-2927.
12. Drew P., Xu J., Storer P., Chavis J., Racke M. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders. Neurochemistry International 2006, 49:183-189.
13. Engel T., Hernández F., Avila J., Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. Journal of Neuroscience 2006, 25:5083-5090.
14. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data. Behavioural Brain Research 1988, 31:47-59.
15. Fazil M., Shadab, Baboota S., Sahnim J.K., Ali J. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future. Journal of Drug Targeting 2012, 20:97-113.
16. Frozza R.L., Bernardi A., Paese K., Hoppe J.B., da Silva T., Battastini A.M., et al. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. Journal of Biomedical Nanotechnology 2010, 6:694-703.
17. Frozza R.L., Bernardi A., Hoppe J.B., Meneghetti A.B., Matté A., Battastini A.M., et al. Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Molecular Neurobiology 2013, 47:1066-1080.
18. Garwood C.J., Pooler A.M., Atherton J., Hanger D.P., Noble W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Discussion 2011, 2:1-9.
19. Ge Y.W., Lahiri D.K. Regulation of promoter activity of the APP gene by cytokines and growth factors: Implications in Alzheimer's disease. Annals of the New York Academy of Sciences 2003, 973:463-467.
20. Ghosh S.S., Massey H.D., Krieg R., Fazelbhoy Z.A., Ghosh S., Sica D.A., et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: Role of inflammation. American Journal of Physiology Renal Physiology 2009, 296:1146-1157.
21. Green H.F., Nolan Y.M. GSK-3 mediates the release of IL-1b, TNF-a and IL-10 from cortical glia. Neurochemistry International 2012, 61:666-671.
22. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science 2002, 6:319-327.
23. Hernández F., Gómez de Barreda E., Fuster-Matanzo A., Lucas J.J., Avila J. GSK3: A possible link between beta amyloid peptide and tau protein. Experimental Neurology 2010, 223:322-325.
24. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry 2008, 104:1433-1439.
25. Huges R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neuroscience Biobehaviour 2004, 28:497-505.
26. Inoue K. Microglial activation by purines and pyrimidines. Glia 2003, 40:156-163.
27. Jäger E., Venturini C.G., Poletto F.S., Colomé L.M., Pohlmann J.P., Bernardi A., et al. Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. Journal of Biomedical Nanotechnology 2009, 5:130-140.
28. Jantas D., Szymanska M., Budziszewska B., Lason W. An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked celldeath in primary cortical neurons. Apoptosis 2009, 14:900-912.
29. Jaques J.A., Doleski P.H., Castilhos L.G., da Rosa M.M., Souza V.D., Carvalho F.B., et al. Free and nanoencapsulated curcumin prevents cigarrete smoke-induced cognitive impairment and redox imbalance. Neurobiology of Learning and Memory 2013, 100:98-107.
30. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., et al. Age-dependent accumulation of solubre beta (Abeta) oligomers reverses neuroprotectvive effect of soleble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. Journal of Biological Chemistry 2011, 286:18414-18425.
31. Johnson-Farley N.N., Travkina T., Cowen D.S. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase 3 by brain-derived neurotrophic factor and insulin-like groth factor-1 in cultured hippocampal neurons. Pharmacology and Experimental Therapeutics 2006, 316:1062-1069.
32. Kar S., Slowikowski S.P., Westaway D., Mount H.T. Interactions between beta-amyloid and central cholinergic neurons: Implications for Alzheime's disease. Journal of Psychiatry and Neuroscience 2004, 29:427-441.
33. Kundu P., Mohanty C., Sahoo S.K. Antiglioma activity of curcumin loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomaterialia 2012, 8:2670-2687.
34. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience 2001, 21:8370-8377.
35. Lucas J.J., Hernández F., Gómez-Ramos P., Morán M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditionaltransgenic ice. EMBO Journal 2001, 20:27-39.
36. Lue L.F., Kuo Y.M., Beach T., Walker D.G. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Molecular Neurobiology 2010, 41:115-128.
37. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. Journal of Neuroscience 2009, 29:9078-9089.
38. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: A short review. Life Sciences 2006, 78:2081-2087.
39. Mazanetz M.P., Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative disease. Nature Reviews 2007, 6:464-479.
40. McAllister A.K., Katz L.C., Lo D.C. Neurotrophins and synaptic plasticity. Annual Review of Neuroscience 1999, 22:295-318.
41. Medeiros R., Prediger R.D.S., Passos G.F., Pandolfo P., Duarte F.S., et al. Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: Relevance for the behavioral and synaptic deficits induced by amyloid β protein. Journal of Neuroscience 2007, 27:5394-5404.
42. Medina J.H., Izquierdo I. Retrograde messengers, long-term potentiation and memory. Brain Research Reviews 1995, 21:185-194.
43. Modi G., Pillay V., Choonara Y.E., Ndesendo V.M.K., du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Progress in Neurobiology 2009, 88:272-285.
44. Murer M., Yanb Q., Raisman-Vozari R. Brain derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Progress in Neurobiology 2001, 63:71-124.
45. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:6990-6995.
46. Ono K., Hasegawa K., Naiki H., Yamada M. Curcuminhas potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of Neuroscience Research 2004, 75:742-750.
47. Pardridge W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
48. Passos G.F., Figueiredo C.P., Prediger R.D.S., Pandolfo P., Duarte F.S., Medeiros R., et al. Role of the macrophage inflammatory protein-1α/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by β-amyloid peptide. American Journal of Pathology 2009, 175:1586-1597.
49. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic, San Diego. 5th ed.
50. Peterson G.L. Review of the Folin-phenol protein quantification method of Lowry, Rosebrough, Farr and Randall. Analytical Biochemistry 1979, 100:201-220.
51. Qin X.Y., Cheng Y., Yu L.C. Potential protection ofcurcumin against intracellular amyloid beta-induced toxicity in cultured rat prefrontal cortical neurons. Neuroscience Letters 2010, 480:21-24.
52. Ralay Ranaivo H., Craft J.M., Hu W., Guo L., Wing L.K., Van Eldik L.J., et al. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. Journal of Neuroscience 2006, 26:662-670.
53. Ray B., Bisht S., Maitra A., Lahiri D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. JAD 2011, 23:61-77.
54. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenicmodel of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. Journal of Neuroscience 2007, 27:1981-1991.
55. Ryder J., Su Y., Ni B. Akt/GSK3b serine/threonine kinases: Evidence for a signaling pathway mediated by familial Alzheimer's disease mutations. Cellular Signalling 2004, 16:187-200.
56. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging 2006, 27:1372-1384.
57. Sofola O., Kerr F., Rogers I., Killick R., Augustin H., Gandy C., et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drodophila model of Alzheimer's disease. PLoS Genetics 2010, 6:e1001087.
58. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. Journal of Cellular and Molecular Medicine 2005, 9:59-71.
59. Song Z., Feng R., Sun M., Guo C., Gao Y., Li L., et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. Journal of Colloid and Interface Science 2011, 354:116-123.
60. Sorrentino G., Bonavita K. Neurodegeneration and Alzheimer's disease: The lesson from tauopathies. Neurological Sciences 2007, 28:63-71.
61. Su C.C., Wang M.J., Chiu T.L. The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma. International Journal of Molecular Medicine 2010, 26:217-224.
62. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology 1991, 30:572-580.
63. Thangapazham R.L., Puri A., Tele S., Blumenthal R., Maheshwari R.K. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology 2008, 32:1119-1123.
64. Tiraboschi P., Hansen L.A., Thal L.J., Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004, 62:1984-1989.
65. Troca-Marín J.A., Alves-Sampaio A., Montesinos M.L. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse modelo f Down's syndrome. Journal of Neuroscience 2011, 31:9445-9455.
66. Tsai Y.M., Chien C.F., Lin L.C., Tsai T.H. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. International Journal of Pharmaceutics 2011, 416:331-338.
67. Tyler W.J., Alonso M., Bramham C.R., Pozzo-Miller L.D. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signalingin hippocampal-dependent learning. Learn Memory 2002, 9:224-237.
68. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
69. Wang H.M., Zhao Y.X., Zhang S., Liu G.D., Kang W.Y., Tang H.D., et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. Journal of Alzheimers Disease 2010, 20:1189-1199.
70. Woodruff-Pak D.S. Animal models of Alzheimer's disease: therapeutic implications. Journal of Alzheimers Disease 2008, 15:507-521.
71. Yang K.Y., Lin L.C., Tseng T.Y., Wang S.C., Tsai T.H. Oral bioavailabil-ity of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical Life Science 2007, 853:183-189.
72. Yasutake C., Kuroda K., Yanagawa T., Okamura T., Yoneda H. Serum BDNF, TNF-a and IL-1b levels in dementia patients. European Archives of Psychiatry and Clinical Neuroscience 2006, 256:402-406.
73. Yoshii A., Constantine-Paton M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nature Neuroscience 2007, 10:702-711.
74. Zanotto-Filho A., Coradini K., Braganhol E., Schröder R., de Oliveira C.M., et al. Curcumin-loaded lipid-core nanocapsules as strategy to improve pharmacological efficacy of curcumin in glioma treatment. European Journal of Pharmaceutics and Biopharmaceutics 2013, 83:156-167.
75. Zhang X., Yin W.K., Shi X.D., Li Y. Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. European Journal of Pharmaceutical Sciences 2011, 42:540-546.